Geoffrey von Maltzahn, Flagship General Partner and co-founder & CEO of Flagship-founded Tessera Therapeutics, explains Tessera's novel gene writing bioplatform and its vast potential for preventing and curing disease.
More from:
Human Health,
Sustainability
Ponsi Trivisvavet, CEO of Inari, Reflects on Her Path to Leadership
Logica Partnership Panel: Pioneering Medicines, Charles River Labs, and Valo Health
Pioneering Women in Biotech
Rare Disease Day is Every Day For Many Families, But it Doesn’t Have to Be
Flagship Celebrates International Day of Women and Girls in Science
